400 Technology Square
About EpizymeEpizyme is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers. We systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found and then design small molecule therapeutics to inhibit the oncogene. The clinical development plan for each of our product candidates is directed towards patients with a particular genetically defined cancer. Our approach is part of a broader trend towards personalized therapeutics based on first identifying the underlying cause of a disease affecting specific patient populations, applying rational drug design tools to create a therapeutic to bind with a molecular target in the identified disease pathway and using a companion diagnostic to select the right patients for treatment.
We have built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic. When Epizyme was founded, we recognized that the HMT class of enzymes might contain many potential oncogenes and, therefore, presented the opportunity to discover, develop and commercialize multiple personalized therapeutics.
We have prioritized 20 HMTs as attractive targets for personalized therapeutics based on their oncogenic potential. Our two most advanced therapeutic product programs target the HMTs DOT1L (for the treatment of mixed lineage leukemia, or MLL-r) and EZH2 (for a genetically defined subtype of non-Hodgkin lymphoma). We believe that our ongoing Phase 1 study for EPZ-5676, targeting DOT1L, is the first clinical trial of an HMT inhibitor. We expect to initiate a Phase 1/2 clinical trial of EPZ-6438 targeting EZH2 in 2Q 2013.
We were founded in 2007 and are led by a management team with extensive experience in the pharmaceutical industry. We have entered into therapeutic collaborations with Celgene, Eisai and Glaxo Group Limited (an affiliate of GlaxoSmithKline), or GSK, that have provided us with approximately $120 million in non-equity funding through March 31, 2013. As of March 31, 2012, we had $85 million in cash and cash equivalents.
224 articles with Epizyme
Epizyme Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the closing of its underwritten public offering of 9,583,334 shares of its common stock at a public offering price of $9.00 per share
Epizyme, Inc. today announced the pricing of an underwritten public offering of 8,333,334 shares of its common stock at a price of $9.00 per share, before underwriting discounts.
Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program
Investor Conference Call Scheduled for Today at 8:30 a.m. EDT
Epizyme, an innovative epigenetic therapy development company, announced this morning that the U.S. Food and Drug Administration has removed their former partial clinical hold reported in April of this year.
There is a new player in the southern California biotech industry. New venture firm Westlake Village BioPartners launched with a $320 million fund and a leadership well familiar with the ins and outs of the biotech and pharma world.
Fulcrum Therapeutics Raises $80 Million Series B From Investors, Including Sanofi and Bill Maris'...
9/5/2018Fulcrum Therapeutics, based in Cambridge, Massachusetts, closed on an $80 million Series B financing.
Epizyme, Inc. today announced that management will present at the following upcoming investor conferences
Conference Call to be Held Today at 8:30 a.m. ET
Cambridge, Massachusetts-based Epizyme emphasized its efforts to move tazemetostat back into clinical trials in its second-quarter financial report.
Epizyme Posts Positive Interim Data for Follicular Lymphoma Treatment, Despite Partial Clinical Hold
6/15/2018Despite some of the troubles Epizyme has seen with its lead drug candidate tazemetostat, including a partial clinical hold placed by the U.S. Food and Drug Administration, the company is pushing forward with positive interim data presented at the 23rd Congress of the European Hematology Association.
Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting
EZM8266 is the first of three new compounds to be named as part of Epizyme’s vision 2020.
Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting
These data from the company's ongoing Phase 2 clinical trial in non-Hodgkin lymphoma (NHL) highlight exploratory response biomarkers and interim correlative data which may have the potential to further refine the clinical application of tazemetostat.
Epizyme Presents Data from a Phase I Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
First presentation of pediatric dose escalation data in tazemetostat, showing favorable safety and tolerability with promising anti-tumor activity.
The webcast can be accessed under "Events and Presentations" in the Investor Relations section of the company's website
Ronald Evans believes he’s much closer to a fat-burning, muscle-growing drug that won’t, uh, give you cancer.